Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% - January 21.08.2026 FJAN.LN IE000MDKBOB3  150,002.00 USD   4,407,668.61   29.384  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Clean Edge Global Water UCITS ETF 21.08.2026 H2O LN IE000Q8F0M81  600,002.00 USD  12,333,989.66   20.557  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - October 21.08.2026 FOCT.LN IE0004X8KUG5  100,002.00 USD   2,980,479.57   29.804  ...

LONDON--(BUSINESS WIRE)--Paysafe unveils video gaming arena, helping publishers and developers reach 19M gamers through discovery, rewards, community and payments....

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - July 21.08.2026 FJUL.LN IE000YJBT6I5  100,002.00 USD   2,925,215.34   29.252  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - April 21.08.2026 FAPR.LN IE000WX2HZQ7  250,002.00 USD   6,537,951.02   26.152  ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) hat heute bekannt gegeben, dass die Europäische Kommission (EK) die Marktzulassung für DAYBU (Trofinetid) zur Behandlung neurobehavioraler Symptome des Rett-Syndroms bei Erwachsenen sowie pädiatrischen Patienten ab fünf Jahren erteilt hat. Damit ist DAYBU das erste und einzige Arzneimittel, das in der Europäischen Union (EU) für diese Indikation zugelassen ist. „Die Zulassung von DAYBU stellt einen wichtigen Meilenstein für...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) heeft vandaag aangekondigd dat de Europese Commissie (EC) een handelsvergunning heeft verleend voor DAYBU (trofinetide) voor de behandeling van neurologische gedragssymptomen van het Rett-syndroom bij volwassenen en pediatrische patiënten van vijf jaar en ouder, waarmee het de eerste en enige goedgekeurde behandeling is voor deze indicatie in de Europese Unie (EU). “De goedkeuring van DAYBU is een belangrijke stap voorwaarts...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) anunció hoy que la Comisión Europea (CE) ha concedido la autorización de comercialización de DAYBU (trofinetida) para el tratamiento de los síntomas neuroconductuales del síndrome de Rett en pacientes adultos y pediátricos de cinco años o más, lo que lo convierte en el primer y único tratamiento aprobado para el síndrome de Rett en la Unión Europea (UE). “La autorización de DAYBU marca un importante hito para la comunidad de...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and ad...